Drugs Made In America Acquisition Corp. Completes $200 Million Initial Public Offering

Deal News | Jan 29, 2025 | EIN

Drugs Made In America Acquisition Corp. Completes $200 Million Initial Public Offering

Drugs Made In America Acquisition Corp., a Cayman Islands-based blank check company, announced the closing of its initial public offering (IPO), raising $200 million. The company is listed on the Nasdaq Global Market under the ticker symbol 'DMAAU'. Each unit of the IPO consists of one ordinary share and a right to receive one-eighth of an ordinary share upon the completion of its first business combination. The firm is primarily targeting business combinations within the pharmaceutical industry, with a focus on reducing U.S. reliance on foreign pharmaceutical manufacturing. The IPO was managed by Clear Street, with legal advice provided by Loeb & Loeb LLP and Winston & Strawn LLP. The SEC declared the registration statement for this offering effective in January 2025.

Sectors

  • Pharmaceuticals
  • Financial Services

Geography

  • United States – The company aims to focus its investments on mitigating risks in the U.S. medical supply chain by investing in domestic manufacturing technologies.
  • Cayman Islands – Drugs Made In America Acquisition Corp. is incorporated as an exempted company in the Cayman Islands.

Industry

  • Pharmaceuticals – Drugs Made In America Acquisition Corp. is focused on pursuing business combinations in the pharmaceutical industry, particularly related to U.S. on-shoring of drug manufacturing.
  • Financial Services – The article discusses the initial public offering (IPO) of Drugs Made In America Acquisition Corp., a financial transaction in the investment sector.

Financials

  • $200,000,000 – Gross proceeds from the initial public offering of Drugs Made In America Acquisition Corp.
  • $10.00 per unit – The price per unit for the IPO, with each unit comprising one ordinary share and one-eighth of an ordinary share upon a business combination.

Participants

NameRoleTypeDescription
Drugs Made In America Acquisition Corp.Target CompanyCompanyA blank check company focused on mergers or acquisitions in the pharmaceutical sector.
Clear StreetBook-running ManagerCompanyActed as the sole book-running manager for the IPO.
Loeb & Loeb LLPLegal Counsel to Drugs Made In AmericaCompanyServed as legal advisors for Drugs Made In America during the IPO.
Winston & Strawn LLPLegal Counsel to Clear StreetCompanyServed as legal advisors for Clear Street in this transaction.